News

Use of ACE inhibitors to treat high blood pressure can sometimes cause swelling (angioedema) episodes, but the prevalence of this potentially life-threatening side effect is not well-known because it is rarely reported, a Danish study into a “drug reaction” database found. The study, “ACE-Inhibitor Related Angioedema Is…

Results of the Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks will be announced by August. The company also announced it has selected KVD824 as an oral preventive therapy for HAE. A Phase 2…

Researchers have identified risk factors that may predispose children to more severe initial angioedema attacks — factors such as male gender, preschool age, presence of fever or hives, and a history of allergies. Epinephrine treatment and receiving care in a pediatric observation unit, on the other hand, were factors that…

Researchers developed a questionnaire, called the Angioedema Control Test (AECT), that may be helpful in monitoring disease control and patient-reported outcomes among people with recurrent angioedema. The tool is described in the journal Allergy, in the study, “Development of the Angioedema Control Test (AECT) – A Patient…

The lack of control of a key enzyme associated with the overproduction of bradykinin seems to be the common root cause of all forms of hereditary angioedema with normal C1-inhibitor activity, a study reports. The study, “Impaired control of the contact system in hereditary angioedema with…

A Thai version of the Angioedema Quality of Life (AE-QoL) questionnaire is a reliable way to measure health-related quality of life in Asian people with recurrent angioedema, a new study demonstrates. The study, “Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change,” was published…

Angioedema News brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important events dealing with angioedema throughout 2019. As a reminder of what mattered most to our readers in 2019, here are the 10 most-read articles of last year, with a brief description of…

KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial conducted by the treatment’s developer, KalVista Pharmaceuticals. DME is a form of angioedema that is caused by the leaking of blood vessels which lead to fluid accumulating in the…

BioCryst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of  berotralstat (BCX7353), a once daily, oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE). The latest results of APeX-S and APeX-2…

With so much recent publicity surrounding gene therapy, it’s no surprise that the topic was a major focus of the recent 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit. From diagnosis and clinical trial design to manufacturing, pricing strategies, and ethical concerns, gene therapy — both its high…